The cystic fibrosis V232D mutation inhibits CFTR maturation by disrupting a hydrophobic pocket rather than formation of aberrant interhelical hydrogen bonds.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Biochemical Pharmacology

• Publication date

  2014-03-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bcp.2013.12.027PMID 24412276
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Corrector VX-809 stabilizes the first transmembrane domain of CFTR.

  2013influential reference
• Bithiazole Correctors Rescue CFTR Mutants by Two Different Mechanisms

  2013influential reference
• Drug Rescue Distinguishes between Different Structural Models of Human P-Glycoprotein

  2013cited by this paper
• Mechanism-based corrector combination restores ΔF508-CFTR folding and function

  2013cited by this paper
• Two Salt Bridges Differentially Contribute to the Maintenance of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel Function*

  2013cited by this paper
• Human P-glycoprotein Contains a Greasy Ball-and-Socket Joint at the Second Transmission Interface*

  2013cited by this paper
• Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction.

  2013cited by this paper
• VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1

  2013influential reference
• Locking Intracellular Helices 2 and 3 Together Inactivates Human P-glycoprotein*

  2013cited by this paper
• Corrector-mediated rescue of misprocessed CFTR mutants can be reduced by the P-glycoprotein drug pump.

  2012cited by this paper
• Fixing cystic fibrosis by correcting CFTR domain assembly

  2012cited by this paper
• Crystal structure of the multidrug transporter P-glycoprotein from C. elegans

  2012cited by this paper
• Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans

  2012cited by this paper
• Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

  2011influential reference
• Increased folding and channel activity of a rare cystic fibrosis mutant with CFTR modulators.

  2011cited by this paper
• The W232R suppressor mutation promotes maturation of a truncation mutant lacking both nucleotide-binding domains and restores interdomain assembly and activity of P-glycoprotein processing mutants.

  2011cited by this paper
• Restoration of domain folding and interdomain assembly by second‐site suppressors of the ΔF508 mutation in CFTR

  2010cited by this paper
• Intragenic Suppressing Mutations Correct the Folding and Intracellular Traffic of Misfolded Mutants of Yor1p, a Eukaryotic Drug Transporter*

  2010cited by this paper
• A Chemical Corrector Modifies the Channel Function of F508del-CFTR

  2010cited by this paper
• The V510D Suppressor Mutation Stabilizes ΔF508-CFTR at the Cell Surface†

  2010cited by this paper
• Identification of Residues in the Drug Translocation Pathway of the Human Multidrug Resistance P-glycoprotein by Arginine Mutagenesis*

  2009cited by this paper
• Molecular models of the open and closed states of the whole human CFTR protein

  2009cited by this paper
• Cooperative assembly and misfolding of CFTR domains in vivo.

  2009cited by this paper
• Mechanisms for rescue of correctable folding defects in CFTRDelta F508.

  2009cited by this paper
• Cystic Fibrosis

  2009cited by this paper
• CFTR function and prospects for therapy.

  2008cited by this paper
• Identification of Putative Binding Sites of P‐glycoprotein Based on its Homology Model

  2008cited by this paper
• Correctors promote folding of the CFTR in the endoplasmic reticulum.

  2008cited by this paper
• Phenylalanine-508 mediates a cytoplasmic–membrane domain contact in the CFTR 3D structure crucial to assembly and channel function

  2008cited by this paper
• Assembly and misassembly of cystic fibrosis transmembrane conductance regulator: folding defects caused by deletion of F508 occur before and after the calnexin-dependent association of membrane spanning domain (MSD) 1 and MSD2.

  2008cited by this paper
• Multiple Membrane-Cytoplasmic Domain Contacts in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mediate Regulation of Channel Gating*

  2008cited by this paper
• Processing Mutations Disrupt Interactions between the Nucleotide Binding and Transmembrane Domains of P-glycoprotein and the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)*

  2008influential reference
• Arginines in the First Transmembrane Segment Promote Maturation of a P-glycoprotein Processing Mutant by Hydrogen Bond Interactions with Tyrosines in Transmembrane Segment 11*

  2008cited by this paper
• Atomic model of human cystic fibrosis transmembrane conductance regulator: Membrane-spanning domains and coupling interfaces

  2008cited by this paper
• Suppressor Mutations in the Transmembrane Segments of P-glycoprotein Promote Maturation of Processing Mutants and Disrupt a Subset of Drug-binding Sites*

  2007cited by this paper
• Correctors Promote Maturation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-processing Mutants by Binding to the Protein*

  2007cited by this paper
• Specific Rescue of Cystic Fibrosis Transmembrane Conductance Regulator Processing Mutants Using Pharmacological Chaperones

  2006cited by this paper
• The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants.

  2006influential reference
• Insertion of an Arginine Residue into the Transmembrane Segments Corrects Protein Misfolding*

  2006cited by this paper
• Structure of a bacterial multidrug ABC transporter

  2006cited by this paper
• Most F508del-CFTR Is Targeted to Degradation at an Early Folding Checkpoint and Independently of Calnexin

  2005cited by this paper
• The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR

  2005cited by this paper
• Cystic fibrosis.

  2005cited by this paper
• Folding of CFTR is predominantly cotranslational.

  2005cited by this paper
• The ΔF508 Mutation Disrupts Packing of the Transmembrane Segments of the Cystic Fibrosis Transmembrane Conductance Regulator*

  2004influential reference
• The DeltaF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator.

  2004cited by this paper
• Methanethiosulfonate Derivatives of Rhodamine and Verapamil Activate Human P-glycoprotein at Different Sites*

  2003cited by this paper
• A Novel Electron Paramagnetic Resonance Approach to Determine the Mechanism of Drug Transport by P-glycoprotein*

  2002cited by this paper
• Introduction of the Most Common Cystic Fibrosis Mutation (ΔF508) into Human P-glycoprotein Disrupts Packing of the Transmembrane Segments*

  2002influential reference
• Interhelical hydrogen bonds in the CFTR membrane domain

  2001influential reference
• Cross-linking of Human Multidrug Resistance P-glycoprotein by the Substrate, Tris-(2-maleimidoethyl)amine, Is Altered by ATP Hydrolysis

  2001cited by this paper
• Cystic fibrosis transmembrane conductance regulator has an altered structure when its maturation is inhibited.

  2000cited by this paper
• Cystic Fibrosis Transmembrane Conductance Regulator Has an Altered Structure When Its Maturation Is Inhibited1

  2000cited by this paper
• The human multidrug resistance P‐glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy

  1999cited by this paper
• The Transmembrane Domains of the Human Multidrug Resistance P-glycoprotein Are Sufficient to Mediate Drug Binding and Trafficking to the Cell Surface*

  1999cited by this paper
• Cystic Fibrosis-associated Mutations at Arginine 347 Alter the Pore Architecture of CFTR

  1999cited by this paper
• Channel-lining residues in the M3 membrane-spanning segment of the cystic fibrosis transmembrane conductance regulator.

  1998cited by this paper
• Correction of Defective Protein Kinesis of Human P-glycoprotein Mutants by Substrates and Modulators*

  1997cited by this paper
• Helix packing in membrane proteins.

  1997cited by this paper
• Disease-associated mutations in cytoplasmic loops 1 and 2 of cystic fibrosis transmembrane conductance regulator impede processing or opening of the channel.

  1997cited by this paper
• Experimentally determined hydrophobicity scale for proteins at membrane interfaces

  1996cited by this paper
• Cytoplasmic Loop Three of Cystic Fibrosis Transmembrane Conductance Regulator Contributes to Regulation of Chloride Channel Activity*

  1996cited by this paper
• Disease-associated Mutations in the Fourth Cytoplasmic Loop of Cystic Fibrosis Transmembrane Conductance Regulator Compromise Biosynthetic Processing and Chloride Channel Activity*

  1996cited by this paper
• P-glycoprotein

  1995cited by this paper
• Rapid Purification of Human P-glycoprotein Mutants Expressed Transiently in HEK 293 Cells by Nickel-Chelate Chromatography and Characterization of their Drug-stimulated ATPase Activities (*)

  1995cited by this paper
• CYSTIC FIBROSIS HETEROZYGOTE RESISTANCE TO CHOLERA TOXIN IN THE CYSTIC FIBROSIS MOUSE MODEL

  1995cited by this paper
• Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model.

  1994cited by this paper
• Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis.

  1993cited by this paper
• Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA

  1989cited by this paper
• Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

  1989cited by this paper
• Rapid and efficient site-specific mutagenesis without phenotypic selection.

  1985cited by this paper

• Supramolecular Sensing Platforms: Techniques for In Vitro Biosensing

  2024cites this paper
• Farewell to single-well: An automated single-molecule FRET platform for high-content, multiwell plate screening of biomolecular conformations and dynamics

  2023cites this paper
• An automated single-molecule FRET platform for high-content, multiwell plate screening of biomolecular conformations and dynamics

  2023cites this paper
• Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR

  2021cites this paper
• CFTR corrector efficacy is associated with occupancy of distinct binding sites

  2021cites this paper
• Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR☆

  2020cites this paper
• Structural dynamics of membrane-protein folding from single-molecule FRET.

  2019cites this paper
• CFTR transmembrane segments are impaired in their conformational adaptability by a pathogenic loop mutation and dynamically stabilized by Lumacaftor

  2019cites this paper
• V232D mutation in patients with cystic fibrosis

  2018cites this paper
• A minimal helical-hairpin motif provides molecular-level insights into misfolding and pharmacological rescue of CFTR

  2018cites this paper
• Structural effects of extracellular loop mutations in CFTR helical hairpins.

  2018cites this paper
• Corrector VX‐809 promotes interactions between cytoplasmic loop one and the first nucleotide‐binding domain of CFTR

  2017cites this paper